Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson’s disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Name | Title | Since | Age |
|---|---|---|---|
| Toru Kimura | President, CEO & Representative Director | 2024 | 66 |
| Tsutomu Nakagawa | Managing Executive Officer & Director | 2024 | 58 |
| Motoyuki Sakai | EVP of Glob. Corp. Strat., Glob. Fin. Admin. Ext. Aff., Corp. Gov., IT Mngt., Data Anly. & Rep. Dir | 2025 | 65 |
| Yoshio Iteya | Outside Independent Director | 2025 | 70 |
| Hisayoshi Kashima | Director | 2025 | 65 |
| Minoru Usui | Independent Outside Director | 2021 | 71 |
| Mayumi Mochizuki | Outside Independent Director | 2025 | 72 |
| Koji Fujimoto | Independent Outside Director | 2022 | 63 |
| Daishiro Michimori | Outside Independent Director | 2025 | 70 |
| Hiroshi Niinuma | Director | 2024 | 68 |